Results 71 to 80 of about 19,125 (215)

Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double‐Blind, Proof‐of‐Concept Study

Arthritis &Rheumatology, EarlyView.
Objective To assess guselkumab + golimumab combination therapy versus guselkumab monotherapy in participants with active psoriatic arthritis (PsA) and inadequate response to tumor necrosis factor inhibitors (TNFi‐IR). Methods Adults with active TNFi‐IR PsA (three or more tender/swollen joints) were randomized (2:1) to subcutaneous guselkumab (100 mg) +
Jose U. Scher, Iain B. McInnes, Enrique R. Soriano, Joseph F. Merola, Paul Bird, Vinod Chandran, Edaire Cheng, Elena Reynoso, Warner Chen, Maoji Li, Lianne S. Gensler, Philip J. Mease, Christopher T. Ritchlin   +12 more
wiley   +1 more source

Machine Learning to Predict Remission Between 6 and 24 Months in Rheumatoid Arthritis: Insights From JAK, an International Registry Collaboration

Arthritis &Rheumatology, EarlyView.
Objective To develop, externally validate, and simplify a machine learning model to predict remission between 6 and 24 months in patients with rheumatoid arthritis (RA) initiating tumor necrosis factor inhibitors, JAK inhibitors, interleukin‐6 inhibitors, abatacept, or rituximab using data from 11 international registries in the JAK‐pot collaboration ...
Zubeyir Salis, Denis Mongin, Denis Choquette, Louis Coupal, Catalin Codreanu, Florenzo Iannone, Roberto Caporali, Tore K. Kvien, Sella Provan, Ruth Fritsch‐Stork, Dan Nordström, Nina Trokovic, Karel Pavelka, Jakub Závada, Ana Rodrigues, Ziga Rotar, Prodromos Sidiropoulos, Irini Flouri, Céline Lamacchia, Michele Iudici, Delphine Courvoisier, Kim Lauper, Axel Finckh   +22 more
wiley   +1 more source

Pharmacological considerations in pharmacotherapy of rheumatology patients with liver disease: a brief narrative review

Rheumatology
The presence of chronic liver diseases such as metabolic dysfunction-associated steatosis liver disease, viral hepatitis, and cirrhosis may affect the treatment plan in patients with rheumatologic disorders, with concern about the adverse effects of the ...
Saeedeh Shenavandeh, Seyed Alireza Taghavi, AliAkbar Nekooeian, Maryam Moini   +3 more
doaj   +1 more source

Adherence to Subcutaneous Anti-Tumour Necrosis Factor Treatment in a Cohort of Patients with Rheumatoid Arthritis Before and After the Implementation of a Comprehensive Care Model

Biologics: Targets & Therapy, 2022
Pedro Santos-Moreno,1 Guillermo Sánchez-Vanegas,2 Angélica Monterrosa-Blanco,3 Gabriel-Santiago Rodríguez-Vargas,1 Manuel Rivero,1 Pedro Rodriguez,1 Omar-Javier Calixto,4 Adriana Rojas-Villarraga,5 Carlos Alberto Castro3 1Rheumatology Department, Biomab ...
Santos-Moreno P, Sánchez-Vanegas G, Monterrosa-Blanco A, Rodríguez-Vargas GS, Rivero M, Rodriguez P, Calixto OJ, Rojas-Villarraga A, Castro CA   +8 more
doaj  

Trial of a new antirheumatic agent.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1974
A double-blind crossover trial of fenoprofen calcium versus acetylsalicylic acid (aspirin) and placebo in 10 outpatients with active rheumatoid arthritis, is reported. Both fenoprofen and aspirin were found to be similarly effective agents in rheumatoid arthritis with an average daily dose of 2,1 g fenoprofen compared with 4,5 g aspirin. No significant
openaire   +3 more sources

Autoantibodies to Joint‐Related Peptides Are Associated With Onset of Rheumatoid Arthritis in Presymptomatic Seronegative Individuals

Arthritis &Rheumatology, EarlyView.
Objective To identify autoantibodies in presymptomatic individuals that associate with the onset of rheumatoid arthritis (RA) and to distinguish early RA from osteoarthritis (OA), particularly in individuals lacking classic RA serologic markers. Methods We analyzed serum and plasma from three cohorts: presymptomatic individuals who later developed RA ...
Outi Sareila, Linda Johansson, Anders Lundquist, Monica Leu Agelii, Lei Cheng, Yibo He, Erik Lönnblom, Maria Andersson, Jan Kihlberg, Anders Esberg, Inger Gjertsson, Rikard Holmdahl, Solbritt Rantapää‐Dahlqvist   +12 more
wiley   +1 more source

Cytomegalovirus retinitis during upadacitinib monotherapy for rheumatoid arthritis: a case report

Journal of Rheumatic Diseases
Janus kinase inhibitors (JAKis) are associated with increased risk of Varicella-Zoster Virus reactivation, particularly in Asian populations. While reactivation of cytomegalovirus (CMV) is very rare in rheumatoid arthritis (RA) patients on JAKis, CMV ...
Sang Jun Park, Yun Jong Lee
doaj   +1 more source

Determinants of Difficult‐to‐Manage and Treatment‐Refractory Axial Spondyloarthritis: A Cross‐Sectional Analysis Within a Longitudinal Cohort

Arthritis &Rheumatology, EarlyView.
Objective The purpose of this study was to estimate the prevalence of difficult‐to‐manage (D2M) and treatment‐refractory (TR) axial spondyloarthritis (axSpA) and to identify factors associated with D2M and TR disease in a longitudinal cohort. Methods We performed a cross‐sectional analysis on data from the Schroeder Arthritis Institute Spondylitis ...
Patricia Remalante‐Rayco, Laura Passalent, Tina Chim, Hannah Vijayan, Manal Alnasser, Zeynep Baskurt, Robert D. Inman, Nigil Haroon, Denis Poddubnyy   +8 more
wiley   +1 more source

Deep Immunophenotyping Reveals Distinct Immune Signatures in Axial Spondyloarthritis and Psoriatic Arthritis

Arthritis &Rheumatology, EarlyView.
Objective Axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) are overlapping yet distinct conditions within the SpA spectrum. As divergent immunophenotypes may influence disease course and therapeutic response, we compared immune cell subsets, cytokine profiles, and inflammatory mediators.
Natalie Frede, Nils Craig‐Müller, Silke Kohrt, Marei‐Theresa Bott, Ulrich Salzer, Ana Cecilia Venhoff, Jens Thiel, Julia Frede, Reinhard E. Voll, Marta Rizzi, Raquel Lorenzetti, Nils Venhoff   +11 more
wiley   +1 more source

Evaluation of impaired growth plate development of long bones in skeletally immature mice by antirheumatic agents. [PDF]

J Orthop Res, 2021
Caron MMJ, van Rietbergen B, Castermans TMR, Haartmans MJJ, van Rhijn LW, Welting TJM, Witlox AMA.   +6 more
europepmc   +1 more source